This cross-sectional study evaluates the association between corticolimbic vulnerability to tau pathology as a continuous trait with clinicalpathologic heterogeneity and glial activation patterns in neuropathologically diagnosed Alzheimer disease. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.